[go: up one dir, main page]

WO2015066452A3 - Methods of treating pediatric cancers - Google Patents

Methods of treating pediatric cancers Download PDF

Info

Publication number
WO2015066452A3
WO2015066452A3 PCT/US2014/063384 US2014063384W WO2015066452A3 WO 2015066452 A3 WO2015066452 A3 WO 2015066452A3 US 2014063384 W US2014063384 W US 2014063384W WO 2015066452 A3 WO2015066452 A3 WO 2015066452A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pediatric cancers
treating pediatric
treating
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/063384
Other languages
French (fr)
Other versions
WO2015066452A2 (en
Inventor
Siraj Mahamed ALI
Juliann CHMIELECKI
Matthew J. HAWRYLUK
Philip James STEPHENS
Kai Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foundation Medicine Inc
Original Assignee
Foundation Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation Medicine Inc filed Critical Foundation Medicine Inc
Publication of WO2015066452A2 publication Critical patent/WO2015066452A2/en
Publication of WO2015066452A3 publication Critical patent/WO2015066452A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and compositions for treating pediatric cancers are disclosed.
PCT/US2014/063384 2013-11-01 2014-10-31 Methods of treating pediatric cancers Ceased WO2015066452A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898835P 2013-11-01 2013-11-01
US61/898,835 2013-11-01

Publications (2)

Publication Number Publication Date
WO2015066452A2 WO2015066452A2 (en) 2015-05-07
WO2015066452A3 true WO2015066452A3 (en) 2015-06-04

Family

ID=53005386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/063384 Ceased WO2015066452A2 (en) 2013-11-01 2014-10-31 Methods of treating pediatric cancers

Country Status (1)

Country Link
WO (1) WO2015066452A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179391B2 (en) 2017-05-05 2021-11-23 Fuyao Zhang Compound with kinase inhibitory activity and preparation method and use thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
UA125503C2 (en) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
UA121669C2 (en) 2015-02-20 2020-07-10 Інсайт Корпорейшн BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
WO2017165617A1 (en) * 2016-03-23 2017-09-28 Dana-Farber Cancer Institute, Inc. COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
CN106011051B (en) * 2016-07-01 2020-01-21 中山大学 Application of Bend5 protein in improving differentiation of embryonic stem cells into primitive germ-like cells by induction
WO2018081204A1 (en) * 2016-10-26 2018-05-03 Li George Y DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE
MX393780B (en) 2017-01-17 2025-03-24 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
CN111989107A (en) 2018-03-19 2020-11-24 阿瑞雅德制药公司 Methods of treating cancer in pediatric patients
SI3788047T1 (en) 2018-05-04 2024-11-29 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CN112566912A (en) 2018-05-04 2021-03-26 因赛特公司 Salts of FGFR inhibitors
WO2020170355A1 (en) * 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Method for treating fgfr1 mutated tumor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
JP2020162420A (en) 2019-03-28 2020-10-08 シスメックス株式会社 Method for determining sensitivity of cyclin-dependent kinase 4/6 inhibitor, reagent kit, device and computer program
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021257568A1 (en) * 2020-06-16 2021-12-23 Alnylam Pharmaceuticals, Inc. ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068030A1 (en) * 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
WO2012108782A1 (en) * 2011-02-07 2012-08-16 Общество С Ограниченной Ответственностью "Онкомакс" Antibody that stops or slows tumour growth (variants)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068030A1 (en) * 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
WO2012108782A1 (en) * 2011-02-07 2012-08-16 Общество С Ограниченной Ответственностью "Онкомакс" Antibody that stops or slows tumour growth (variants)
US20140105821A1 (en) * 2011-02-07 2014-04-17 llya Valer'evich Tymofeev Antibody that stops or slows tumour growth (variants)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALI ET AL.: "Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients", CANCER RES, vol. 74, 15 October 2014 (2014-10-15) *
BRESLER ET AL.: "Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma", SCI TRANSL MED, vol. 3, no. 108, 9 November 2011 (2011-11-09), pages 108RA114 1 - 10 *
DIECI ET AL.: "Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.", CANCER DISCOV, vol. 3, no. 3, March 2013 (2013-03-01), pages 264 - 279 *
HOWMAN-GILES ET AL.: "Neuroblastoma and other neuroendocrine tumors.", SEMIN NUCL MED., vol. 37, no. 4, July 2007 (2007-07-01), pages 286 - 302 *
JONES ET AL.: "Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma", NAT, vol. 45, no. 8, 2013, pages 927 - 932 *
LEW W ET AL.: "The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations", SCI SIGNAL, vol. 2, no. 58, 17 February 2009 (2009-02-17), pages RA6 1 - 11 *
MYUNG ET AL.: "Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors", TRANSL ONCOL, vol. 5, no. 6, December 2012 (2012-12-01), pages 430 - 436 *
RAND ET AL.: "Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas", PROC NAT ACAD SCI, vol. 102, no. 40, 4 October 2005 (2005-10-04), pages 14344 - 14349 *
SAMPSON ET AL.: "A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma", FRONT ONCOL, vol. 3, no. 132, 31 May 2013 (2013-05-31), pages 1 - 12 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179391B2 (en) 2017-05-05 2021-11-23 Fuyao Zhang Compound with kinase inhibitory activity and preparation method and use thereof

Also Published As

Publication number Publication date
WO2015066452A2 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
WO2015066452A3 (en) Methods of treating pediatric cancers
IL273090B (en) Methods and compositions for the treatment of cancer
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
EP3060207A4 (en) Methods and compositions for treating cancer
EP3027192A4 (en) Methods for the treatment of solid tumors
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
EP3024497A4 (en) Methods and compositions for treating brain diseases
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3004396A4 (en) Methods and compositions for the treatment of cancer
AU2017246547A1 (en) Methods of treating pediatric cancers
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
EP3052102A4 (en) Compositions and methods for treating cancers
EP3082427A4 (en) Compositions and methods for treatment of glaucoma
EP3008212A4 (en) Methods of treatment of cancer
EP3004395A4 (en) Compositions and methods for treating cancer
EP3065829A4 (en) Compositions and methods for treating melanoma
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
PL2968478T3 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP3154544A4 (en) Compositions and methods for treating cancers
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
EP2991650A4 (en) Methods for the treatment of cancer
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EP2984185A4 (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14858779

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14858779

Country of ref document: EP

Kind code of ref document: A2